以下文章来源于肥胖世界ObesityWorld ，作者欢迎订阅 肥胖世界ObesityWorld . 《肥胖世界》Obesity World - 同步传真肥胖及代谢国际新学术进展，为医学减重临床、教研人员搭建一座与国际接轨的桥梁，「每医健」旗下内容平台。 基础代谢提升，冬季燃脂效率加码 在冬天，身体为了抵御低温、保持体温，会自动消耗更多能量，这让基础代谢率自然上升。同样的锻炼，冬季燃烧的热量往往比暖和的季节 更多，仿佛体内开启了"燃脂加速档"，能让你的运动成效加倍显著。 ➤ 脂肪合成变慢，减脂更给力 气温降低时，人体合成脂肪的速度会减缓。同时，身体会更积极地分解棕色脂肪来产热。如果此时以科学方式锻炼，不仅能燃烧更容易积累 的白色脂肪，还有助于消除难减的"顽固脂肪"，让你的瘦身成果更加牢靠。 ➤ 运动感受更棒，耐力提升更容易 冬季凉爽的气候，避免了夏天运动时心率飙升和大汗淋漓的不适，户外跑步或徒步等有氧运动体验更舒适，不仅更乐于坚持，还能更容易突 破自身的耐力极限。 解锁冬季"高效减脂"模式的几个关键要点： 04 睡眠要充足 高质量的睡眠有助于维持瘦素水平，帮助抑制食欲。避免熬夜，保证每晚7-8小时的睡眠，让身 ...

整理 | GLP1减重宝典内容团队 ▍ 研究显示，司美格鲁肽 的作用原理与之前认为的不同 一项新研究表明，司美格鲁肽、替尔泊肽等减肥药 似乎直接影响新陈代谢，而不仅仅是食欲。 人们以前认为这些药物（统称为胰高血糖素样肽 1 (GLP-1) 类似物）的作用原理是让人感觉更饱，从而吃得更少。 但最近的一项临床试验结果表明事情 并非如此简单 。每天服用 GLP-1 24 周的人体重减轻，新陈代谢也加快。 他们减掉的体重越多，他们的新陈代谢似乎受到的影响就越大，而在研究开始时新陈代谢较慢的人似乎获得的好处最多。 ▍实验证实 司美格鲁肽也在直接影响新陈代谢 研究负责人唐纳·奥谢教授在一份声明中表示："我认为这些新疗法只是让人们吃得更少，这种想法过于简单了。因此，这项研究让我们 对治疗肥胖症的新药的作用机制有了更深入的了解，这是一个令人兴奋的进步。" "研究结果还提供了科学依据，证明肥胖的治疗不仅仅是少吃多动——这只是预防措施。治疗远比这复杂得多。" 图中的蓝色司美格鲁肽注射笔。司美格鲁肽，更常见的名称是 Ozempic，是一种 GLP-1 类似物，可以帮助人们控制血糖和减肥。 GLP-1 类似物是应用最广泛的减肥药物， ...

Core Insights - The article discusses the health implications of going to bed hungry, highlighting that it can lead to an "energy crisis" in the body, affecting sleep quality and increasing cortisol levels, which may contribute to weight gain [6][7]. Group 1: Health Implications of Hunger - Going to bed hungry can trigger sympathetic nervous system responses, leading to increased heart rate and blood pressure, which negatively impacts sleep quality [6]. - Hunger increases cortisol secretion, a stress hormone that can lead to heightened appetite and fat accumulation, particularly in the abdominal area [6]. Group 2: Consequences of Poor Sleep and Eating Habits - A cycle can develop where hunger leads to poor sleep, resulting in fatigue and increased hunger the next day, which may lead to binge eating and deteriorating health [7]. - Eating late-night snacks, especially high-sugar and high-fat foods, can disrupt deep sleep and cause significant blood sugar fluctuations [9]. Group 3: Recommendations for Healthy Eating Before Sleep - To balance health and sleep, it is suggested to consume light, easily digestible foods if hungry, such as warm milk, unsweetened yogurt, oatmeal, bananas, or almonds [10]. - It is recommended to finish eating 1 to 2 hours before bedtime, with a portion size of 100-150 kilocalories to alleviate hunger without burdening the body or sleep [10].

Core Insights - The article highlights the clinical development of ASC37, a novel oral GLP-1R/GIPR/GCGR triagonist peptide by Gilead Sciences, showcasing its significant pharmacokinetic advantages over existing treatments [5][7]. Group 1: Drug Development - ASC37 has entered clinical development as of November 30, with a notable oral bioavailability of 4.2%, which is approximately 9 times, 30 times, and 60 times higher than semaglutide, tirzepatide, and retatrutide, respectively [5]. - The drug's development leverages Gilead's two core technology platforms: AI-assisted drug discovery and enhanced oral peptide delivery technology [5]. - In non-human primate studies, ASC37 demonstrated an average apparent half-life of about 56 hours, supporting once-daily or even less frequent dosing [7]. Group 2: Efficacy and Exposure - ASC37 exhibited a drug exposure level (measured by area under the curve) approximately 57 times greater than that of retatrutide, indicating a higher amount of active substance entering systemic circulation for enhanced efficacy [7]. - The drug's activity levels in activating GLP-1R, GIPR, and GCGR receptors were approximately 5 times, 4 times, and 4 times higher than retatrutide, respectively [5]. Group 3: Regulatory Plans - Gilead plans to submit a new drug clinical trial application for ASC37 to the FDA for obesity treatment in the second quarter of 2026 [7].

以下文章来源于体重管理三年行动 ，作者体重管理三年行动 体重管理三年行动 . 响应国家"健康中国2030"战略，落实"体重管理年"三年行动，本账号发布权威资讯 2025年4月，国家卫生健康委携手国家中医药局联合发布《关于做好健康体重管理门诊设置与管理工作的通知》，明确要求国家及省级综合医 院、儿童医院和中医医院，须在2025年6月底前基本实现体重管理门诊的全面覆盖。 这一政策的出台，正式拉开了全国医院体系体重管理门诊建设的序幕，充分展现了国家对日益严峻的超重与肥胖问题所采取的积极应对之策。 | 首页 | 工作动态 | 政策文件 | 关于我们 | 返回主站 > | | --- | --- | --- | --- | --- | | 政策文件 | | | | Q 影现在所在位置: 首页>欧贸文件 | | | 关于做好健康体重管理门诊设置与管理工作的通知 | | | | | | 发布时间：2025-04-11 来源: 西政司 | | | A A B | | | | | | 国卫办医政函(2025) 113号 | 肥胖困境：体重异常已经成为国民健康的重大隐患 目前，我国体重异常问题已演变为影响广泛的重大公共健康挑战。 ...

整理 | GLP1减重宝典内容团队 ▍礼来：新晋"减肥药之王"的崛起 2025年第三季度，礼来报告替尔泊肽（糖尿病用Mounjaro＋肥胖症用Zepbound）季度销售额突破100亿美元，进入全球最畅销药物之 列。截至2025年9月，礼来在美国GLP-1药物处方份额达到58%，诺和诺德为42%。替尔泊肽因显著优于司美格鲁肽的减重幅度与代谢 改善效果，被视为"下一代减肥药"的代表。 过去几年，GLP-1受体激动剂的代表药物——诺和诺德的司美格鲁肽（Ozempic/Wegovy）掀起全球减肥与糖尿病治疗热潮，推动公司 成 为 欧 洲 市 值 最 高 的 医 药 企 业 之 一 。 然 而 随 着 礼 来 的 加 入 ， 行 业 格 局 迅 速 变 化 。 礼 来 的 双 靶 点 激 动 剂 替 尔 泊 肽 （Mounjaro/Zepbound）凭借更强的控糖与减重效果正在快速蚕食市场份额。在此背景下，诺和诺德股价近期出现明显回落，而礼来 则迎来新一轮估值上升。 ▍诺和诺德：昔日霸主的滑落 截至2025年底，诺和诺德股价显著下行，单日跌幅曾超过9%–12%。核心原因是其旗舰减肥与糖尿病药物需求不及预期，同时公司下 ...

Core Insights - The article discusses a recent study indicating that GLP-1 receptor agonists, popular weight loss medications, may not only reduce waist circumference and control blood sugar but also potentially diminish the effects of alcohol [5][8]. Summary by Sections What are GLP-1 Drugs? - GLP-1 drugs, such as Semaglutide (Ozempic and Wegovy) and Tirzepatide (Mounjaro), mimic natural hormones that regulate blood sugar and appetite [7]. Study Results - The study involved 20 obese adults, half of whom had taken GLP-1 drugs for at least four weeks. Participants consumed a measured amount of alcohol after fasting, aiming for a breath alcohol concentration of 0.08. Those on GLP-1 drugs reported feeling less intoxicated and experienced a delayed onset of alcohol effects due to slower gastric emptying [8]. - Participants taking GLP-1 drugs exhibited lower drinking desires, and nausea and blood sugar changes were similar between both groups, suggesting that reduced intoxication was not due to discomfort [8]. Limitations and Future Research Directions - The study is a small-scale preliminary trial without random assignment, focusing solely on obese patients. More research is needed to determine the drugs' effectiveness, long-term effects, and optimal dosages for blood sugar control and alcohol reduction [9]. - Experts caution that the findings do not establish causation and highlight the need for future studies to track overall alcohol consumption and drinking desires to assess potential compensatory behaviors [9]. Potential in Addiction Treatment - Emerging data suggest that GLP-1 drugs may play a role in addiction treatment, as GLP-1 receptors influence reward signals for food, alcohol, and nicotine. If validated in larger studies, these drugs could bridge endocrinology and behavioral health, shifting public focus from weight loss to broader medical applications [10].

肥胖世界ObesityWorld . 《肥胖世界》Obesity World - 同步传真肥胖及代谢国际新学术进展，为医学减重临床、教研人员搭建一座与国际接轨的桥梁，「每医健」旗下内容平台。 以下文章来源于肥胖世界ObesityWorld ，作者欢迎订阅 生酮饮食近年风靡全球，其"高脂不增重"的特性吸引无数减重人士尝试。这种不必"避雷"脂肪却能瘦身的饮食方案，究竟魔力何在？ 传统观点认为，生酮饮食主要通过诱导体内酮体产生，促使身体转向消耗脂肪作为能量来源。然而，科学家们发现其减重机制远不止于此， 如某些研究表明生酮饮食能显著提升能量消耗率。 复旦大学人类表型组研究院洪尚宇、郑琰团队最新研究成果在《自然·代谢》发表，揭示了生酮饮食减重的全新机制。研究发现，生酮饮食 会改变特定肠道菌群丰度，降低其产生的胆盐水解酶(BSH)水平，从而导致小鼠血液中牛磺脱氧胆酸(TDCA)和牛磺熊脱氧胆酸(TUDCA)显 著升高。这两种物质能抑制肠道碳酸酐酶1表达，直接阻断卡路里吸收过程。 这一发现在涵盖四百余人的临床观察研究中得到验证，研究者认为TDCA和TUDCA有望成为治疗肥胖及其并发症的潜在药物靶点。 为深入探索生酮饮食的减 ...

整理 | GLP1减重宝典内容团队 新研究表明，通过生活方式指导，量身定制、减少剂量的司美格鲁肽可以有效防止体重反弹。 在意大利威尼斯举行的欧洲肥胖症大会 (ECO) 上，最新研究结果强调了在减肥计划中使用个性化司美格鲁肽剂量的优势。这项研究由 Embla 开展，Embla 是一家数字减肥诊所，它的首席研究员兼首席医疗官 Henrik Gudbergsen 博士是这项研究的带头人。 ▍ 研究发现，较低剂量与较高剂量同样有效，并且慢慢减少药量同时注重改变生活方式可防止体重反弹 胰高血糖素样肽-1 (GLP-1) 受体激动剂（如司美格鲁肽）在帮助人们减肥方面非常有效。通过模仿一种名为 GLP-1 的激素的作用，它 们可以 减少食欲和饥饿感，减缓食物从胃中释放的速度，并增加进食后的饱腹感。 然而，它们会引起腹泻、恶心、呕吐、头晕和头痛等副作用，并且许多患者在停止服药后很快就会恢复大部分减掉的体重。 然而，最近的研究表明，在服用减肥药的同时，接受营养和运动指导以及解决情绪化饮食相关问题的支持的患者不太可能反弹。一些研 究还表明，缓慢停药可能有助于防止体重反弹。 Embla 的研究人员感兴趣的是是否有可能通过调整司美格 ...

Core Viewpoint - The article emphasizes the urgent need for a national initiative to combat obesity in China, highlighting the launch of a three-year "Weight Management Year" action plan in response to rising obesity rates and associated health risks [5][22]. Obesity Status - China is facing an unprecedented obesity crisis, with adult overweight rates reaching 34.3% and obesity rates at 16.4% as of 2018, marking increases of 50.4% and 130.9% respectively since 2002 [9]. - The obesity rates among children and adolescents are alarming, with overweight rates at 11.1% and obesity rates at 7.9% for ages 6-17, and a 10.4% obesity rate for children under 6 [9]. - Projections indicate that by 2030, adult overweight and obesity rates could exceed 70%, while rates for children and adolescents may reach 31.8%, particularly in rural areas [9]. Disease Burden Associated with Obesity - Obesity is a significant risk factor for various chronic diseases, including type 2 diabetes, cardiovascular diseases, and certain cancers [11]. - Individuals with obesity are 3 to 7 times more likely to develop diabetes compared to those with normal weight, with hypertension and hyperlipidemia rates being 2.8 times and 2.3 times higher, respectively [11]. - The economic burden of obesity-related healthcare costs exceeds 200 billion yuan annually, accounting for 12% of total chronic disease expenditures [13]. Weight Management Action Plan - The "Weight Management Year" initiative aims to enhance public awareness and skills related to weight management, targeting a 10% annual reduction in obesity rates by 2026 [22]. - By 2030, the plan seeks to establish a supportive environment for weight management, promote healthy lifestyles, and reduce the upward trend of overweight and obesity in the population [22].